Difference in the occurrence of cardiovascular events according to class of antihypertensive agent, based on a follow-up study of Japanese hypertension patients

被引:0
作者
Uchiyama, M [1 ]
Kondo, T [1 ]
Tsuzuki, Y [1 ]
Zhu, S [1 ]
Tamakoshi, K [1 ]
Sakakibara, H [1 ]
Uchiyama, S [1 ]
Toyoshima, H [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Field Social Life Sci, Dept Publ Hlth Hlth Informat Dynam,Showa Ku, Nagoya, Aichi 4668550, Japan
来源
JAPANESE HEART JOURNAL | 2001年 / 42卷 / 05期
关键词
hypertension; follow-up study; cardiovascular event; antihypertensive agent; stroke; short acting calcium antagonist;
D O I
10.1536/jhj.42.585
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We conducted a nested case-control study to evaluate the relationship between antihypertensive agent class and the incidence of initial cardiovascular events. A total of 7,443 patients being treated with an antihypertensive agent in 1985-1986 were enrolled for follow-up of up to 5 years. A total of 362 patients (186 males and 176 females) developed cardiovascular events, Age (5-year interval) and sex-matched controls were then randomly selected. A multiple logistic regression analysis was done to control for the effects Of Confounding factors. The results showed that the use of diuretics and beta -blockers was associated with a reduced risk of cardiovascular events (odds ratio [OR] =0.65, 95% confidence interval [CI]: 0.49-0.86, and OR=0.75, 95% Cl: 0.56-1.02, respectively), against a significantly raised risk associated with the use of calcium antagonists (OR=1.34, 95% Cl: 1.03-1.80). However, as far as stroke was concerned, there was no significant association of risk with the use of any agent. The control group was found to be similar to the case group with respect to the changes in the treatment program during the Follow-up period. The results suggest that the calcium antagonists used in Japan during the period of 1985-1990 constituted a potential risk for the occurrence of cardiovascular events.
引用
收藏
页码:585 / 595
页数:11
相关论文
共 25 条
[1]  
AMERY A, 1985, LANCET, V1, P1349
[2]  
[Anonymous], 1993, Blood Press, V2, P62
[3]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[4]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[5]   MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION) [J].
DAHLOF, B ;
LINDHOLM, LH ;
HANSSON, L ;
SCHERSTEN, B ;
EKBOM, T ;
WESTER, PO .
LANCET, 1991, 338 (8778) :1281-1285
[6]   Use of calcium antagonists in patients with ischemic heart disease and systemic hypertension [J].
Frishman, WH ;
Michaelson, MD .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (10A) :33-38
[7]   NIFEDIPINE - DOSE-RELATED INCREASE IN MORTALITY IN PATIENTS WITH CORONARY HEART-DISEASE [J].
FURBERG, CD ;
PSATY, BM ;
MEYER, JV .
CIRCULATION, 1995, 92 (05) :1326-1331
[8]   Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension:: the Nordic Diltiazem (NORDIL) study [J].
Hansson, L ;
Hedner, T ;
Lund-Johansen, P ;
Kjeldsen, SE ;
Lindholm, LH ;
Syvertsen, JO ;
Lanke, J ;
de Faire, U ;
Dahlöf, B ;
Karlberg, BE .
LANCET, 2000, 356 (9227) :359-365
[9]   CALCIUM-ANTAGONISTS IN THE TREATMENT OF ISCHEMIC-HEART-DISEASE - MYOCARDIAL-INFARCTION [J].
HELD, PH ;
YUSUF, S .
CORONARY ARTERY DISEASE, 1994, 5 (01) :21-26
[10]  
*HLTH WELF STAT AS, 1996, J HLTH WELFARE STAT, V43, P86